Saol Therapeutics News

The latest news from Saol Therapeutics, we have a late-stage portfolio of products & proprietary platform technologies that seek to address significant unmet needs - pain, spasticity, & rare metabolic disorders.

April 17, 2025
Saol Therapeutics Announces Major Clinical Milestones Across Multiple Development Programs
January 28, 2025
Saol Therapeutics announces FDA acceptance of New Drug Application for SL1009 for treatment of Pyruvate Dehydrogenase Complex Deficiency
December 3, 2024
Saol Therapeutics Announces Submission of New Drug Application (NDA) to the U.S. FDA for SL1009
October 30, 2024
Saol Therapeutics Announces Positive Topline Results from the SL-1002 RAISE Limb Spasticity Trial
October 22, 2024
Saol Therapeutics Announces Topline Data from the SL-1002 RAISE Limb Spasticity Trial to be Presented at Spasticity X – the First International Spasticity Symposium – on October 25, 2024
May 1, 2024
EY Announces Dave Penake of Saol Therapeutics as an Entrepreneur Of The Year® 2024 Southeast Award Finalist
February 12, 2024
Saol Therapeutics Receives Fast Track Designation for Treatment of Rare Mitochondrial Disease – Pyruvate Dehydrogenase Complex Deficiency (PDCD)
September 19, 2023
Saol Therapeutics Announces Completion of Enrollment in Both the Phase II COMPASS Osteoarthritis Knee Pain Trial and the Phase II RAISE Limb Spasticity Trial
April 12, 2023
Saol Therapeutics Announces Advancement into the Efficacy Expansion Cohort of the Phase II COMPASS Trial Evaluating the Safety and Efficacy Profile of SL-1002 for Treatment of Knee Pain Associated with Osteoarthritis
March 16, 2023
Saol Therapeutics enhances its IP portfolio for Dichloroacetate (DCA; SL-1009) in Glioblastoma and Rare Pediatric Cancers
February 13, 2023
Saol Therapeutics Receives Golden Helix Innovation Award from the Center for Global Health Innovation
October 4, 2022
Saol Therapeutics Announces Enrollment Achievement in Pivotal Phase 3 Trial For Rare Mitochondrial Disease – Pyruvate Dehydrogenase Complex Deficiency (PDCD)
August 9, 2022
Saol Therapeutics Announces First Patient Enrolled in Phase II COMPASS Trial Evaluating the Safety and Efficacy Profile of SL-1002 for Treatment of Knee Pain Associated with Osteoarthritis
May 3, 2022
Saol Therapeutics Announces First Patient Enrolled in Phase II RAISE Spasticity Trial Evaluating the Safety Profile of SL-1002 for Limb Spasticity
April 26, 2022
Saol Therapeutics and InformedDNA Partner to Offer Genetic Counseling to Patients with Rare Mitochondrial Disease
March 1, 2022
Saol Therapeutics and GeneDx, Inc. Collaborate to Detect Patients with Rare Mitochondrial Disease
January 5, 2022
Amneal Acquires Saol Therapeutics’ Baclofen Franchise
December 6, 2021
Saol Therapeutics Announces FDA Approval of LYVISPAHTM (baclofen) Oral Granules and the Divesture of its Plasma-derived Hyperimmune Portfolio
January 11, 2019
Saol Therapeutics Announces that CDC Website has Been Updated to Reflect Wide Availability of VARIZIG® (Varicella Zoster Immune Globulin [Human])
June 30, 2017
Ipsen announces Dysport® (abobotulinumtoxinA) co-promotion agreement with Saol Therapeutics to expand commercial reach in the United States

Interested in learning more?